Peder Frederiksen

Jul 1, 2023 | mdpi.com | Federica Genovese |Peder Frederiksen |Anne-Christine Bay-Jensen |Morten A. Karsdal

Abstract:Nitisinone has been approved for treatment of alkaptonuria (AKU). Non-invasive biomarkers of joint tissue remodelling could aid in understanding the molecular changes in AKU pathogenesis and how these can be affected by treatment. Serological and urinary biomarkers of type I collagen and II collagen in AKU were investigated in patients enrolled in the randomized SONIA 2 (NCT01916382) clinical study at baseline and yearly until the end of the study (Year 4).

May 30, 2023 | mdpi.com | Mylène P. Jansen |Anne-Christine Bay-Jensen |Peder Frederiksen |Stefania Kalogera

1. IntroductionOsteoarthritis (OA) is the most common form of arthritis and is characterized by chronic pain and disability [1]. The main hallmarks of OA include cartilage degradation, osteophyte formation, subchondral bone remodeling, and inflammation of the synovium. Joint pain is the most common clinical OA manifestation; however, the association between structural changes and pain is still not completely understood.